Genethon SA:製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Genethon SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C10799)・商品コード:DATA904C10799
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:35
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Genethon SA (Genethon) is a non-profit biotherapy research and development organization which designs and develops gene therapy products for rare diseases. The company is developing gene therapy products for the treatment of limb girdle myophaties, duchenne muscular dystrophy, myotubular myopathy, spinal muscular atrophy, and huntington’s disease among others. Genethon conducts research programs, investments in technological innovation, pre-clinical assessment platforms, bio-production, quality control, translational development, research up to clinical validation, and biomanufacturing services. The organization is developing medicines for rare neuromuscular diseases, liver diseases, blood and eye disorders. It works in collaboration with other research institutes such as Children’s Hospital, Boston Great Ormond Street Hospital for clinical immunodeficiency developments. The organization is funded by Association Francaise contre les Myopathies(AFM-Telethon). Genethon is headquartered in Paris, France.

Genethon SA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Genethon SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genethon SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genethon SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genethon SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Genethon SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Genethon SA, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 10
Orchard Therapeutics Enters into Agreement with Genethon 11
Sarepta Therapeutics Enters into Research Agreement with Genethon 12
Genethon and CRISPR Therapeutics Enter into Research Agreement 13
NanoMedSyn Enters into Agreement with Genethon 14
Selecta Biosciences Enters into Research Agreement with Genethon 15
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 16
GenSight Biologics Enters into Agreement with Genethon 17
Licensing Agreements 19
Spark Therapeutics Enters into Licensing Agreement with Genethon 19
Miltenyi Biotec Enters into Licensing Agreement with Genethon 20
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 21
CEVEC Pharma Enters into Licensing Agreement with Genethon 23
Genethon SA – Key Employees 24
Genethon SA – Locations And Subsidiaries 25
Head Office 25
Recent Developments 26
Product News 26
Sep 26, 2017: Dynacure joins ongoing Natural History Study in Centronuclear Myopathies with the Institute of Myology (France) 26
07/27/2017: Sarepta Therapeutics Announces its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data in Nature Communications 27
Jul 25, 2017: Microdystrophin restores muscle strength in Duchenne muscular dystrophy 28
Apr 17, 2017: New step towards the treatment of myotubular myopathy: gene therapy restores strength and prolongs lives in affected dogs 29
03/24/2017: Action Duchenne Funding Gene Therapy to Advance Treatments for Duchenne 30
Jan 26, 2017: Gene therapy for Pompe disease effective in mice, poised for human trials 31
Jan 11, 2018: Genethon welcomes interim data of a phase I / II clinical trial with a gene therapy product developed in its laboratories 33
Clinical Trials 34
Jul 25, 2017: Microdystrophin restores muscle strength in Duchenne muscular dystrophy 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Genethon SA, Pharmaceuticals & Healthcare, Key Facts 2
Genethon SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genethon SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Genethon SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genethon SA, Deals By Therapy Area, 2012 to YTD 2018 8
Genethon SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
AveXis Enters into Licensing Agreement with Genethon and Centre National de la Recherche Scientifique 10
Orchard Therapeutics Enters into Agreement with Genethon 11
Sarepta Therapeutics Enters into Research Agreement with Genethon 12
Genethon and CRISPR Therapeutics Enter into Research Agreement 13
NanoMedSyn Enters into Agreement with Genethon 14
Selecta Biosciences Enters into Research Agreement with Genethon 15
Audentes Therapeutics Enters Into Co-Development Agreement With Genethon For AT001 16
GenSight Biologics Enters into Agreement with Genethon 17
Spark Therapeutics Enters into Licensing Agreement with Genethon 19
Miltenyi Biotec Enters into Licensing Agreement with Genethon 20
GenSight Biologics Enters into Licensing Agreement with AFM, Genethon and Inserm Transfert 21
CEVEC Pharma Enters into Licensing Agreement with Genethon 23
Genethon SA, Key Employees 24

List of Figures
Genethon SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genethon SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genethon SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genethon SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genethon SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Genethon SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Genethon SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Genethon SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★調査レポート[Genethon SA:製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C10799)販売に関する免責事項を必ずご確認ください。
★調査レポート[Genethon SA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆